Delivering on the Promise of Purity

Pfanstiehl Inc. is a US based cGMP Manufacturer of High Purity, High Quality, Low Endotoxin and Low Metal components such as Trehalose, Sucrose, Mannitol, Maltose, Galactose (non-animal), Mannose and Amino Acids such as Arginine, Histidine, Methionine and Glutamine for Biologics, Biosimilars, Vaccines, Cell Culture Media and Injectables (liquid & lyo) located in Waukegan, Illinois, USA. These products are utilized as critical stabilization components or process and upstream ingredients in many approved and marketed Biopharmaceuticals worldwide.

New Launches: Methionine (M168) and Glutamine (G167)

Pfanstiehl can provide full technical as well as regulatory support for our products incld. DMF filings in USA as well as in China and has tremendous manufacturing capacity for these critical biopharma ingredients.  All of Pfanstiehl’s products are multi-compendial and having industry leading quality specifications. Pfanstiehl has been in operation since 1919, focusing on both Biopharmaceutical excipients / critical components & Pharmaceutical HPAPIs / APIs (generic and on contract manufacturing base). Pfanstiehl specializes in isolation, purification, custom synthesis and scale-up development of regulated, high purity and low endotoxin Injectable Formulation Ingredients, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, in gram to multi-ton commercial quantities.

Pfanstiehl, Inc.
1219 Glen Rock Avenue
Waukegan, IL 60085-6230

USA Telephone: +1 847-623-0370
Toll Free Number: +1 800-383-0126
Europe Telephone: +41 41 755 40 54

Email: cs@pfanstiehl.com
Website: www.pfanstiehl.com

Go to article: Home | What's in a nameGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Lactalis IngredientsGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: BEA TechnologiesGo to article: NatoliGo to article: In DepthGo to article: What’s in a name: Agencies struggle to keep up with new drug names Go to article: How gene therapies can transform sickle cell disease treatment Go to article: Childproof packaging: How things are changing for consumer drugsGo to article: BIO-Europe 2023: Pharma balances on shaky financial and legislative footingGo to article: Reform in South Korea means progression in improving time to reimbursement Go to article: Q&A: UK pharma manufacturing prepares for imminent shake up in 2024 Go to article: Bio Image SystemsGo to article: PfanstiehlGo to article: ListingsGo to article: EventsGo to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue